Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
NCT05061550 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 630
Last updated 2026-05-22
Summary
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
Conditions
Interventions
- DRUG
-
Participants will receive Durvalumab via intravenous route.
- DRUG
-
Oleclumab
Participants will receive Oleclumab via intravenous route.
- DRUG
-
Monalizumab
Participants will receive Monalizumab via intravenous route.
- DRUG
-
Dato-DXd
Participants will receive datopotamab deruxtecan (Dato-DXd) via intravenous route.
- DRUG
-
AZD0171
Participants will receive AZD0171 via intravenous route.
- DRUG
-
Carboplatin as chemotherapy
- DRUG
-
Cisplatin as chemotherapy
- DRUG
-
Pemetrexed/Cisplatin
Pemetrexed/Cisplatin as chemotherapy
- DRUG
-
Pemetrexed/Carboplatin
Pemetrexed/Carboplatin as chemotherapy
- DRUG
-
Carboplatin/Paclitaxel
Carboplatin/Paclitaxel, as chemotherapy
- DRUG
-
Volrustomig
Participants will receive Volrustomig via intravenous route.
- DRUG
-
Participants will receive Rilvegostomig via intravenous route.
Sponsors & Collaborators
-
Parexel
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Tina Cascone, MD · MD Anderson Cancer Center Houston, TX 77030
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 95 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-04-14
- Primary Completion
- 2030-05-28
- Completion
- 2030-05-28
- FDA Drug
- Yes
Countries
- United States
- Belgium
- Canada
- France
- Hungary
- Ireland
- Italy
- Portugal
- South Korea
- Spain
- Taiwan
- Turkey (Türkiye)
Study Locations
More Related Trials
-
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
NCT05925530 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy
NCT00063154 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies
NCT04042558 ·Status: COMPLETED ·Phase: PHASE2
-
Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer
NCT04061590 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
NCT06284317 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
NCT02937818 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
NCT04832854 ·Status: TERMINATED ·Phase: PHASE2
-
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients
NCT04205552 ·Status: RECRUITING ·Phase: PHASE2
-
Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients
NCT03081689 ·Status: COMPLETED ·Phase: PHASE2
-
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
NCT03739710 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment
NCT01497041 ·Status: UNKNOWN ·Phase: PHASE2
-
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
NCT06632327 ·Status: RECRUITING ·Phase: PHASE3
-
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
NCT01443078 ·Status: COMPLETED ·Phase: PHASE2
-
Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)
NCT03319316 ·Status: WITHDRAWN ·Phase: PHASE2
-
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
NCT07153445 ·Status: RECRUITING ·Phase: PHASE2
-
Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer
NCT03030131 ·Status: TERMINATED ·Phase: PHASE2
-
Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC
NCT00291850 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)
NCT00240097 ·Status: COMPLETED ·Phase: PHASE2
-
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer
NCT03847519 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
NCT06926673 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy
NCT04249362 ·Status: COMPLETED ·Phase: PHASE2
-
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
NCT04367311 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer
NCT03237377 ·Status: TERMINATED ·Phase: PHASE2
-
Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.
NCT01750281 ·Status: COMPLETED ·Phase: PHASE2